FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800245419> ?p ?o ?g. }

• W2800245419 endingPage "1677" @default.
• W2800245419 startingPage "1677" @default.
• W2800245419 abstract "<h3>Importance</h3> The effect of ticagrelor with or without aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) is unknown. <h3>Objective</h3> To compare the effect of ticagrelor + aspirin or ticagrelor alone vs aspirin alone on saphenous vein graft patency 1 year after CABG. <h3>Design, Setting, and Participants</h3> Randomized, multicenter, open-label, clinical trial among 6 tertiary hospitals in China. Eligible patients were aged 18 to 80 years with indications for elective CABG. Patients requiring urgent revascularization, concomitant cardiac surgery, dual antiplatelet or vitamin K antagonist therapy post-CABG, and who were at risk of serious bleeding were excluded. From July 2014 until November 2015, 1256 patients were identified and 500 were enrolled. Follow-up was completed in January 2017. <h3>Interventions</h3> Patients were randomized (1:1:1) to start ticagrelor (90 mg twice daily) + aspirin (100 mg once daily) (n = 168), ticagrelor (90 mg twice daily) (n = 166), or aspirin (100 mg once daily) (n = 166) within 24 hours post-CABG. Neither patients nor treating physicians were blinded to allocation. <h3>Main Outcomes and Measures</h3> Primary outcome was saphenous vein graft patency 1 year after CABG (FitzGibbon grade A) adjudicated independently by a committee blinded to allocation. Saphenous vein graft patency was assessed by multislice computed tomographic angiography or coronary angiography. <h3>Results</h3> Among 500 randomized patients (mean age, 63.6 years; women, 91 [18.2%]), 461 (92.2%) completed the trial. Saphenous vein graft patency rates 1 year post-CABG were 88.7% (432 of 487 vein grafts) with ticagrelor + aspirin; 82.8% (404 of 488 vein grafts) with ticagrelor alone; and 76.5% (371 of 485 vein grafts) with aspirin alone. The difference between ticagrelor + aspirin vs aspirin alone was statistically significant (12.2% [95% CI, 5.2% to 19.2%];<i>P</i> < .001), whereas the difference between ticagrelor alone vs aspirin alone was not statistically significant (6.3% [95% CI, –1.1% to 13.7%];<i>P</i> = .10). Five major bleeding episodes occurred during 1 year of follow-up (3 with ticagrelor + aspirin; 2 with ticagrelor alone). <h3>Conclusions and Relevance</h3> Among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone. Further research with more patients is needed to assess comparative bleeding risks. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT02201771" @default.
• W2800245419 created "2018-05-17" @default.
• W2800245419 creator A5000045667 @default.
• W2800245419 creator A5015994263 @default.
• W2800245419 creator A5025445070 @default.
• W2800245419 creator A5025453964 @default.
• W2800245419 creator A5029390345 @default.
• W2800245419 creator A5083353087 @default.
• W2800245419 creator A5090270861 @default.
• W2800245419 date "2018-04-24" @default.
• W2800245419 modified "2023-10-15" @default.
• W2800245419 title "Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting" @default.
• W2800245419 cites W111766519 @default.
• W2800245419 cites W1233989772 @default.
• W2800245419 cites W1553345686 @default.
• W2800245419 cites W2004925697 @default.
• W2800245419 cites W2024141041 @default.
• W2800245419 cites W2066270370 @default.
• W2800245419 cites W2102860654 @default.
• W2800245419 cites W2113753184 @default.
• W2800245419 cites W2122779695 @default.
• W2800245419 cites W2140501627 @default.
• W2800245419 cites W2141358924 @default.
• W2800245419 cites W2156202966 @default.
• W2800245419 cites W2156255513 @default.
• W2800245419 cites W2156266070 @default.
• W2800245419 cites W2162948289 @default.
• W2800245419 cites W2169387542 @default.
• W2800245419 cites W2190454287 @default.
• W2800245419 cites W2336744020 @default.
• W2800245419 cites W2765697464 @default.
• W2800245419 cites W4205255916 @default.
• W2800245419 cites W4292528167 @default.
• W2800245419 doi "https://doi.org/10.1001/jama.2018.3197" @default.
• W2800245419 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5933396" @default.
• W2800245419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29710164" @default.
• W2800245419 hasPublicationYear "2018" @default.
• W2800245419 type Work @default.
• W2800245419 sameAs 2800245419 @default.
• W2800245419 citedByCount "153" @default.
• W2800245419 countsByYear W28002454192018 @default.
• W2800245419 countsByYear W28002454192019 @default.
• W2800245419 countsByYear W28002454192020 @default.
• W2800245419 countsByYear W28002454192021 @default.
• W2800245419 countsByYear W28002454192022 @default.
• W2800245419 countsByYear W28002454192023 @default.
• W2800245419 crossrefType "journal-article" @default.
• W2800245419 hasAuthorship W2800245419A5000045667 @default.
• W2800245419 hasAuthorship W2800245419A5015994263 @default.
• W2800245419 hasAuthorship W2800245419A5025445070 @default.
• W2800245419 hasAuthorship W2800245419A5025453964 @default.
• W2800245419 hasAuthorship W2800245419A5029390345 @default.
• W2800245419 hasAuthorship W2800245419A5083353087 @default.
• W2800245419 hasAuthorship W2800245419A5090270861 @default.
• W2800245419 hasBestOaLocation W28002454191 @default.
• W2800245419 hasConcept C126322002 @default.
• W2800245419 hasConcept C141071460 @default.
• W2800245419 hasConcept C164705383 @default.
• W2800245419 hasConcept C168563851 @default.
• W2800245419 hasConcept C2776820930 @default.
• W2800245419 hasConcept C2777628954 @default.
• W2800245419 hasConcept C2777849778 @default.
• W2800245419 hasConcept C2779384505 @default.
• W2800245419 hasConcept C2780890252 @default.
• W2800245419 hasConcept C71924100 @default.
• W2800245419 hasConceptScore W2800245419C126322002 @default.
• W2800245419 hasConceptScore W2800245419C141071460 @default.
• W2800245419 hasConceptScore W2800245419C164705383 @default.
• W2800245419 hasConceptScore W2800245419C168563851 @default.
• W2800245419 hasConceptScore W2800245419C2776820930 @default.
• W2800245419 hasConceptScore W2800245419C2777628954 @default.
• W2800245419 hasConceptScore W2800245419C2777849778 @default.
• W2800245419 hasConceptScore W2800245419C2779384505 @default.
• W2800245419 hasConceptScore W2800245419C2780890252 @default.
• W2800245419 hasConceptScore W2800245419C71924100 @default.
• W2800245419 hasIssue "16" @default.
• W2800245419 hasLocation W28002454191 @default.
• W2800245419 hasLocation W28002454192 @default.
• W2800245419 hasLocation W28002454193 @default.
• W2800245419 hasLocation W28002454194 @default.
• W2800245419 hasOpenAccess W2800245419 @default.
• W2800245419 hasPrimaryLocation W28002454191 @default.
• W2800245419 hasRelatedWork W2037327849 @default.
• W2800245419 hasRelatedWork W2295055355 @default.
• W2800245419 hasRelatedWork W2513748005 @default.
• W2800245419 hasRelatedWork W2578926377 @default.
• W2800245419 hasRelatedWork W2584710856 @default.
• W2800245419 hasRelatedWork W2802232330 @default.
• W2800245419 hasRelatedWork W2911330885 @default.
• W2800245419 hasRelatedWork W3087029252 @default.
• W2800245419 hasRelatedWork W3132116249 @default.
• W2800245419 hasRelatedWork W4318820671 @default.
• W2800245419 hasVolume "319" @default.
• W2800245419 isParatext "false" @default.
• W2800245419 isRetracted "false" @default.
• W2800245419 magId "2800245419" @default.
• W2800245419 workType "article" @default.